Drug intelligence / Profile preview

CPG211

Development stage: Preclinical
Lead developer: Alephoson
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies
Administration: Intravitreal

Overview

CPG211 is a preclinical-stage non-viral gene therapy being developed by Alephoson for the treatment of retinal vascular diseases, including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). The therapy utilizes Alephoson's proprietary Cell-Penetrating Gene (CPG) platform, which employs a peptide-based delivery system to transport therapeutic DNA plasmids into retinal cells. This approach is designed to provide sustained intraocular expression of therapeutic proteins, potentially reducing the treatment burden associated with frequent intravitreal injections of conventional biologics.

Beyond the preview

Go deeper on CPG211.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CPG211.

Explore the full profile